Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CI-135 CAR-T in Relapsed/Refractory AML
NCT06760260Phase 1Recruiting
- Sponsor
- Shanghai HRAIN Biotechnology
- Start
- Jan 2022
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CI-135 CAR-T cells in acute myeloid leukemia (AML), sponsored by Shanghai HRAIN Biotechnology. Primary endpoint: Dose Limited Toxicity. Started Jan 2022; status: recruiting.
02
Drugs
CI-135 CAR-T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06760260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06760260.